

Date: January 24, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: ONESOURCE
--	--

Dear Madam/ Sir,

Sub: Addendum to Press Release [Original Press Release dated January 23, 2026]:

This is to inform that there was a minor typographical error in the Press Release dated [January 23, 2026], disseminated to the stock exchanges in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertaining to the unaudited financial results for the quarter ended December 31, 2025.

The error was in para with heading 'FY 28 Guidance Reaffirmation' in the first page, wherein we had inadvertently mentioned "*₹400 million in organic revenue and ₹500 million including recently proposed acquisitions*", *instead of* "*\$400 million in organic revenue and \$500 million including recently proposed acquisitions*".

The corrected press release is attached and we confirm that this change does not impact the financials or disclosures made therein.

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as above

OneSource Q3FY26 Results; Transitional Quarter – Revenue Deferred Pending Customer Approvals for Semaglutide in Canada

Q3FY26 Performance Highlights

- Revenues at ₹2,903 million, down 26% YoY, impacted by delayed semaglutide approvals in Canada
- EBITDA at ₹173 million, down 88% YoY, due to lower revenue in the quarter and largely fixed cost base
- Adjusted PAT stood at (₹472) million with adjusted EPS of (₹4.1)
- Effective interest rate (EIR) below 9%, 200bps lower YoY

FY28 Guidance Reaffirmation

- \$400 million in organic revenue and \$500 million including recently proposed acquisition, with a ~40% EBITDA margin outlook, subject to shareholder approvals
- Organic business targeting ROCE¹ above 50% and Net-to-EBITDA below 1.5x

1. Goodwill and Scheme Intangibles arising from the business combination is excluded from the ROCE calculation as it is not reflective of operating performance in the absence of common control. Capital employed excludes new capital investment in progress.

Bangalore, India, January 23, 2026 - OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26).

Financial Highlights (In ₹ million)

Particulars	Q3FY26	Q2FY26	Q3FY25	YoY
Revenues	2,903	3,758	3,926	(26%)
EBITDA	173	1,065	1,419	(88%)
EBITDA %	6%	28%	36%	(3,018 bps)
Adjusted PAT ¹	(472)	449	672	-
Adjusted EPS ¹	(4.1)	3.9	6.2	-

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q3FY26: ₹71m, Q2FY26: Nil, Q3FY25: ₹1,005m) and scheme related intangible amortisation (Q3FY26: ₹344m, Q2FY26: ₹344m, Q3FY25: ₹355m)

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high.”

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,400 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

<p>Institutional Investors Anurag Bhagania CFO</p> <p>Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com</p>	<p>Corporate Communication Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com</p> <p>Abhilash Mukherjee: +91 89044 28907 Email: abhilash,mukherjee@onesourcecdmo.com</p> <p>Harsh Sheth: +91 9870631557 Email: harsh.sheth@msslgroup.com</p>
---	--